Answers are grounded in this paper and cite their sources.
Allogenic bone marrow transplant (BMT) is a proven curative treatment for sickle cell disease (SCD). Individuals undergoing BMT are monitored using chimerism assays to assess donor cell engraftment. This assay does not reflect engraftment of erythrocytes, which are the essential cell types required to cure SCD. We present a droplet digital PCR (ddPCR) assay capable of detecting reticulocyte‐derived β‐globin RNA alleles (β A and β S ) from whole blood. As globin RNA is specific to red cells, restricted to reticulocytes and not present in erythrocytes, and is in high abundance, it is the ideal biomarker to monitor donor engraftment. Sickle cell disease patients (HbSS) do not have any healthy β A ‐globins and therefore any β A transcript detected must be donor derived. We compared globin allele detection in whole blood and CD71 + reticulocytes isolated from the same samples and found no significant difference in assay performance (correlation r 2 > 0.9). Therefore, removing the need to isolate reticulocytes saved time and associated costs, making it better suited to diagnostic services. The assay can be used from day 0 but in successful transplants it is informative from day 6 post‐transplant. Transfused blood contains reticulocytes and the target allele (β A ‐globin RNA). Transfusions therefore interfere with transplant monitoring, but the interference is short‐lived, being cleared in 2 days. We demonstrate that ddPCR is a simple and effective method for monitoring red cell engraftment in the first 3 weeks post‐transplant.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: